Accelerator
Meeting Point
{AMP IV}
Fourth Edition (16th December 2021)
VIRTUAL
From bench to Market:
The Accelerator Meeting Point
drives the biomedical
innovation in Bellvitge
The AMP IV is organised by IDIBELL’s Business Development & Innovation Area and aims to offer lifescience companies and investors a preferential access to innovative projects at different stages of development.
The innovative projects presented will cover the following fields: oncology, regenerative medicine, mental health, metabolic diseases, infectious diseases (COVID-19) and sepsis. The proposed solutions will include assets in drug development, diagnostic and medical devices from digital therapeutics technologies
Projects
ROOM 1
APTADEL: RNA Aptamer technology for the treatment of Ewing Sarcoma
(Dr. Oscar Martínez / IDIBELL)
First-in-Class anticancer treatment with its patient selection biomarker to overcome tumor progression in advanced cancer patients
(Dr. Oriol Casanovas and Dra. Gabriela Jiménez / IDIBELL – ICO)
SUCCIPRO: First-in-class therapy for inflammatory and metabolic diseases
(Dr. Isabel Huber Ruano / IISPV)
LoopDx: A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection
(Dr. Enrique Hernandez / LoopDx))
KronoSafe® Temporary Pacemaker Fixation System
(Dr. Ray Vicente Miralles / ISABIAL))
T-Cell Therapeutics
(Dr. Bernat Soria / ISABIAL)
Endoscopic Smart Center
(Dr. Lucas Rovira Soriano / IIS La Fe)
Repositioning of a drug for spinal muscular atrophy
(Dr. Piotr Tadeusz Konieczny / INCLIVA)
Saving lives by reducing hospital mortality from sepsis and other acute inflammatory processes.
(Dr. Pablo Pelegrín, Dr. Carlos García, Sr. Joaquín Gómez / IMIB)
ROOM 2
Regeneration Of Sinusoidal Niches To Preserve Hematopoiesis After Chemotherapy On Ageing
(Dra. Carolina Florian / IDIBELL)
Dna Damage Repair Deficit In Cancer Cells
(Dr. Miquel Angel Pujana / IDIBELL -ICO)
Therapy in your Pocket: Effectiveness of Serious Games in Behavioral Addictions (GAME4HEALTH)
(Dra. Susana Jiménez / IDIBELL- HUB)
Inhibition of the miR-424/503 cluster to improve reprogramming efficiency for the generation of iPSCs
(Dr. David Llobet and Dra. Ruth Rodríguez / IDIBELL and IDIBELL- UB)
Tackling radiation-induced enteritis
(Dr. Jordi Guiu / IDIBELL)
PPAR-alpha/gamma AGONISTS
(Dra. Nuria Cabedo Escrig / INCLIVA)
aCUP-E: Advance Cup Electrode for Newborns
(Dr. Albert Fabregat and Dr. Vicenç Pascual / IISPV and URV)
NYSTAREC: Development of a new device to diagnose and treat benign paroxysmal positional vertigo in primary care and emergency departments
(Dr. Josep Lluis Ballvé / IDIAP)
Prostact. Prostate palpation device for prostate cancer screening.
(Dr. César David Vera Donoso / IIS La Fe )
Device for UCI Patients
(Dra. Gemma Via / IDIBELL )
Agenda
This fourth edition will be VIRTUAL, and the conference will consist in two rooms, dividing the projects according to their state of development, establishing 10 projects per room with a total of 20 in the event.
The Investment room mainly dominated by investors and the R + D / Collaboration room will be highlighted by the presence of biotechnology and health sector companies.
At the end of the projects presentations in front of the investors and companies, there is the possibility of selecting the projects that have raised their interest, and B2B meeting will be scheduled to their availability in the following days.
Opening and Welcome:
Gabriel Capellá, IDIBELL Director
Project Pitching Sesion 1
- Virtual Room 1 (Investment):
9:35h - First-in-Class anticancer treatment with its patient selection biomarker to overcome tumor progression in advanced cancer patients.
9:55h - SUCCIPRO: First-in-class therapy for type 2 diabetes
10:15h - LoopDx: A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection
10:35h - T-Cell: Therapeutics
9:15h - Regeneration of Sinusoidal niches to preserve hematopoiesis after chemotherapy on ageing
9:35h - PPAR-alpha/gamma Agonists
9:55h - Therapy in your pocket: Effectiveness of serious games in behavioral addictions (GAME4HEALTH)
10:15h - Inhibition of the miRNA-424/503 cluster to improve reprogramming efficiency for the generation of iPSCs
10:35h - Prostact: Postate palpation device for prostate cancer screening
Break
Project Pitching Sesion 2
- Virtual Room 1 (Investment):
11:10h - Repositioning of a drug for spinal muscular atrophy
11:30h - KronoSafe® Temporary Pacemaker Fixation System
11:50h - Endoscopic Smart Center
12:10h - Saving lives by reducing hospital mortality from sepsis and other acute inflammatory processes
12:30h - APTADEL: Pre-clinical stage drug development biotech company based on RNA Aptamer technology for the treatment of cancer.
- Virtual Room 2 (R+D/Collaboration):
11:10h - Boosting intestinal regeneration to tackle enteritis
11:30h - aCUP-E: Advance Cup Electrode for Newborns
11:50h - Development of a new device to diagnose and treat benign paroxysmal positional vertigo in primary care and emergency departments: NYSTAREC Project.
12:10h - DNA Damage Repair Deficit In Cancer Cells
12:30h - Device for UCI Patients
Closing & B2B meetings
Previous editions
2020
AMP III (3rd edition)
The most innovative technology projects in the healthcare sector were presented this November 26th at the third edition of the AMP III organized by the Business Development and Innovation Area of the Bellvitge Biomedical Research Institute (IDIBELL). An event that this time has been held virtually to ensure the safety of all participants. The digital meeting allowed different IDIBELL entrepreneurs and invited entities from the HealthTech/Biotech sector to espouse their projects to investors and pharmaceutical companies to obtain financing.
RESEARCHERS 2020
Dr. Oriol Casanovas
Dr. Josep Maria Aran
Dr. Oscar Martinez-Tirado
Dr. Rafael Mañez
Dr. Manel Cascalló
Dr. Joan Gilavert
Dra. Antonella Consiglio
Dra. Sara Larriba
Dr. Thomas Golda
Dr. David Garcia Molleví
Dra. Ethelvina Queralt
Dr. Jordi Guiu
Dra. Bárbara Rivera Polo
Dr. José Expósito Ollero (INCLIVA)
Dra. Clara Gomez (FISABIO)
Dr. Jose Alberola / Roberto García (IIS La Fe)
Dr. José Luis García Gimenez (INCLVA)
Dr. Xavier Ruiz Plazas (IISPV)
Dr. Roberto de la Rica (IdisBa)
GUESTS 2020
More than 20 companies from the sector participated in the virtual meeting: 12 venture capital companies and investors, 7 pharmaceutical and biotechnology companies, and 3 regulatory and consulting agencies as a panel of experts to assess the feasibility of the projects and obtain their valuable feedback.
Among the companies participating in the panel of experts, this third edition stands out for the presence of international investors, such as Aurora Science and Gimv. At the local level, we could have the feedback from an investment fund such as In vivo Capital Partners or Canaan Research and Investment, as well as from DDR at the regulatory level.
2019
AMP II (2nd edition)
Bellvitge Biomedical Research Institute (IDIBELL) celebrated the second edition of its Accelerator
Meeting Point (AMP), restating the success of the previous edition. This meeting is organised by IDIBELL’s business development and innovation area and aims to offer investors preferential access to innovation projects in their early stages.
RESEARCHERS 2019
Dr. Oriol Casanovas
Dr. Josep Maria Aran
Dr. Josep Maria Grinyó
Dra. Ethel Queralt
Dra. Maria Jose Linares
Dr. Angel Raya
Dr. Oscar Martinez-Tirado
Dra. Virginia Nunes
Dra. Eva Gonzalez
GUESTS 2019
Jordi Naval – BIOCAT
Michael Tadrós – Fundación Botín
Raül Delgado-Morales – IDIBELL
Marina Rigau Resina – IDIBELL
Esther Riambau – UPF
Laura Rodríguez Gallego – Healthequity
Ignasi Eras – Nina Capital
Melqui Calzado- CataloniaBio
Andrea Sáez – ASABYS
Sylvain Sachot – ASABYS
Lucas Martinez – DCN
Yuki Hasegawa – Whiz partners
Christoph Massner – Earlybird
Jöel Jean-Mairet – Ysios
Mireia Angulo Parera – Caixa C.R.
Sara Sanz – Inveready
Skyla Rabadi – Ship2B
Marc Ramis – Life BioScience
Francisco Armero – Cross Road Biotech
Pablo Cabello – Clave Mayor
2018
AMP I (1st edition)
The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its
Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health
companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and
health sector in Catalonia- and Health Equity -Venture capital of the Barcelona Medical Associationspent
a day with researchers in order to provide recommendations for research projects at a stage
two to three years prior to reaching a commercial milestone.
RESEARCHERS 2018
Dr. Carles Soriano
Dra. Monica Povedano
Dra. Sara Larriba
Dra. Eva Gonzalez
Dr. Daniel Lorenzo
Dr. Josep Maria Aran
Dr. Francisco Ciruela
Dra. Mariona Graupera
Dr. Oriol Casanovas
Dr. Àngel Raya
Dra. Àngels Fabra
GUESTS 2018
CataloniaBio
Biocat
Health Equity
Chasing Science
Universal Doctor
With the aim of strengthening the future Mediterranean alliance AIISEM (Alianza de Innovación e Industralización Sanitaria del Eje Mediterráneo), the fourth edition of the AMP will also count with the participation projects from the following research centers/institutions: ISABIAL, IDIAP, FISABIO, INCLIVA, IIS la Fe, IMIB and IISPV.
Team
Innovation & Business Development Team
Mario de la Cuesta
Head of Innovation Portfolio
Gisela Gallego
Commercialization Unit Senior Officer
Marta Castillejo
Innovation Portfolio Project Manager
Isaac Aran
Commercialization Unit Officer
Laia Traveset
Innovation Portfolio Project Manager
Contact
Innovation & Business Development Area
C/ Feixa Llarga, s/n 08907 L'Hospitalet de Llobregat (Barcelona)
Tef. 932 607 775 ext. 3309innovacio@idibell.cat
- L1 - Estació "Hospital de Bellvitge"
- 65 - L80 - L81 -L86- L87 - L95 - EA - L1 - L2- L10 - L70 - L72